Why the study?
There may be important differences between individual tricyclic antidepressants regarding their overdose toxicity and cardiac toxicity during clinical use.
Do individual tricyclic antidepressants differ in their risk of overdose fatality and cardiovascular adverse events during clinical use?
Population
30 reports of mortality in overdose and 14 observational studies of clinical use
Comparison
Individual tricyclic antidepressants compared for overdose toxicity and cardiovascular risk in clinical use
Design
Systematic review
Authors
Loading...
Warrants restricting TCA use in patients with CV risk; extends observational safety data for individualized selection.
Do individual tricyclic antidepressants differ in their risk of overdose fatality and cardiovascular adverse events during clinical use?
Individual TCAs vary significantly in their overdose fatality and clinical cardiotoxicity risks, suggesting their use should be minimized given these safety concerns.
Taylor et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: